ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,22
-1,51%
Dow Jones
42 732,13
0,80%
DAX
19 906,08
-0,49%
Brent Oil
76,495
0,00%
Bitcoin
98 103,39
0,00%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. ABVC BioPharma Inc (ABVC)

  7. ABVC BioPharma Inc (ABVC) Actualités

ABVC

ABVC BioPharma (ABVC)

ABVC BioPharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ABVC
DateHeureSourceTitreSymboleSociété
19/12/202414h30GlobeNewswire Inc.ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21NASDAQ:ABVCABVC BioPharma Inc
11/12/202412h30GlobeNewswire Inc.ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three PartnersNASDAQ:ABVCABVC BioPharma Inc
15/11/202421h31Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
15/11/202401h33Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ABVCABVC BioPharma Inc
14/11/202415h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
14/11/202415h00GlobeNewswire Inc.ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational MilestonesNASDAQ:ABVCABVC BioPharma Inc
14/11/202414h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABVCABVC BioPharma Inc
22/10/202414h45GlobeNewswire Inc.ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic PartnersNASDAQ:ABVCABVC BioPharma Inc
15/08/202413h30GlobeNewswire Inc.ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsNASDAQ:ABVCABVC BioPharma Inc
07/08/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ABVCABVC BioPharma Inc
02/08/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ABVCABVC BioPharma Inc
26/07/202422h30Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:ABVCABVC BioPharma Inc
17/05/202423h00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
15/05/202423h00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ABVCABVC BioPharma Inc
18/04/202415h25GlobeNewswire Inc.AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareNASDAQ:ABVCABVC BioPharma Inc
17/04/202415h00GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MNASDAQ:ABVCABVC BioPharma Inc
10/04/202414h30GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MNASDAQ:ABVCABVC BioPharma Inc
26/03/202413h30GlobeNewswire Inc.ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MNASDAQ:ABVCABVC BioPharma Inc
21/03/202413h30GlobeNewswire Inc.AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsNASDAQ:ABVCABVC BioPharma Inc
19/03/202413h30GlobeNewswire Inc.ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineNASDAQ:ABVCABVC BioPharma Inc
14/03/202414h30GlobeNewswire Inc.ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateNASDAQ:ABVCABVC BioPharma Inc
27/02/202414h30GlobeNewswire Inc.ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsNASDAQ:ABVCABVC BioPharma Inc
16/02/202423h04Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ABVCABVC BioPharma Inc
15/02/202414h30GlobeNewswire Inc.ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesNASDAQ:ABVCABVC BioPharma Inc
14/02/202401h59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABVCABVC BioPharma Inc
12/02/202414h30GlobeNewswire Inc.ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)NASDAQ:ABVCABVC BioPharma Inc
08/02/202415h17GlobeNewswire Inc.ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per ShareNASDAQ:ABVCABVC BioPharma Inc
12/01/202423h01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ABVCABVC BioPharma Inc
03/01/202413h24GlobeNewswire Inc.ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing FeesNASDAQ:ABVCABVC BioPharma Inc
07/12/202314h30GlobeNewswire Inc.ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:ABVC

Dernières Valeurs Consultées

EU
VIV
Vivendi
NYSE
MRK
Merck
COIN
AVAXUSD
Avalanche
NASDAQ
MSFT
Microsoft
EU
PX4
SBF 120
NASDAQ
AMZN
Amazon.com
COIN
XRPUSD
Ripple
NYSE
KO
Coca Cola
EU
LR
Legrand
COIN
DOGEUSD
Dogecoin
NASDAQ
GOOGL
Alphabet
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés